Investor Relations
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>
Sep 11, 2018
OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock MORE >>
Sep 07, 2018
OPKO Comments on SEC Complaint MORE >>
Sep 04, 2018
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients MORE >>

Press Releases

All Releases
OPKO'S GeneDx Announces Research Collaboration with Radboud University Medical Center
Jan 12, 2018
Aimed at identifying novel genes and pathways to help manage human genetic diseases
OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy
Nov 27, 2017
Enlarged Prostate Affects Approximately 50 Million Men in the U.S.
OPKO Health Reports 2017 Third Quarter Highlights and Financial Results
Nov 08, 2017
RAYALDEE total prescriptions increased 66% in Q3 2017 compared with Q2 2017 4Kscore utilization increased 19% in Q3 2017 compared with Q3 2016 4Kscore TV ads in the Northeast to begin November 21 Submitted a Premarket Approval (PMA) application with FDA for Claros point-of-care (POC) prostate
OPKO Health Submits Premarket Approval Application with FDA for a Point-of-Care PSA Test with the Claros® 1 Platform
Nov 07, 2017
Addresses a $625 million U.S. market opportunity
OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017
Nov 03, 2017
MIAMI , Nov. 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and financial results for the three and nine months ended September 30, 2017 , after the close of the U.S. financial markets on Wednesday, November 8, 2017 .
OPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with Chemotherapy
Oct 26, 2017
OPKO to receive tiered double-digit royalties on product sales
OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan
Oct 12, 2017
OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on product sales
OPKO's BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care
Sep 19, 2017
Providing clinicians with advanced tools to guide quality, value-based care; affiliation to be showcased during the NAACOS Fall 2017 Conference in Washington, DC from Oct. 4-6
OPKO's GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings
Sep 12, 2017
Demonstrates Commitment to Scientific and Clinical Advancement with More Than 35 Poster and Podium Presentations
OPKO Health to Present at Upcoming September Conferences
Aug 31, 2017
MIAMI , Aug. 31, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) ("OPKO" or "the Company"), announces that management will present a corporate update, which will include an update on its hGH development program, at the following upcoming September 2017 investor conferences: 2017 Wells Fargo
OPKO Health Reports Second Quarter 2017 Business and Financial Results
Aug 08, 2017
Conference call begins at 4:30 p.m. Eastern time today
OPKO Health to Announce 2017 Second Quarter Financial Results on August 8, 2017
Aug 03, 2017
MIAMI , Aug. 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months and six months ended June 30, 2017 , after the close of the U.S.
OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
Jun 22, 2017
Updated Guideline Highlights the Limitations of Current Treatments for Secondary Hyperparathyroidism in Patients with Stage 3 or 4 Chronic Kidney Disease and Acknowledges Rayaldee as a Novel Vitamin D Prohormone
OPKO Provides Update to Topline Data of Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults
Jun 15, 2017
MIAMI , June 15, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces an update to the topline data analysis of the Phase 3, double-blind, placebo-controlled study of its investigational long-acting human growth hormone product (hGH-CTP) in adults with growth hormone deficiency (GHD).
OPKO'S GeneDx Extends Relationship with University of California Health for Genetic and Molecular Testing
Jun 07, 2017
OPKO Helps Expand UC Health's leadership at the forefront of precision medicine
OPKO Health Provides Commercial Update for RAYALDEE
Jun 05, 2017
Approximately 68% of all insured lives now have access to RAYALDEE On track to reach 75% of insured lives by year end Increase to 70 field based nephrology sales representatives underway MIAMI , June 05, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces it has entered into
OPKO Health's 4Kscore® Test Highlighted in Podium Presentation at 112th American Urological Association Annual Meeting
May 18, 2017
Prospective study conducted at Veteran Affairs hospitals confirms 4Kscore accurately predicts aggressive prostate cancer
OPKO Announces Multiple Presentations at the 112th American Urological Association Annual Meeting 
May 15, 2017
Highlights 4Kscore's ability to predict aggressive prostate cancer Showcasing 4Kscore and Claros 1 Point-of-Care System at Exhibit Booth #904 MIAMI , May 15, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK) announces that multiple podium and poster presentations highlighting the Company's
CORRECTION -- OPKO Health Inc.
May 09, 2017
MIAMI , May 09, 2017 (GLOBE NEWSWIRE) -- In a release issued earlier today by OPKO Health, Inc. (NASDAQ:OPK), please note that the headline should read "OPKO Health Reports 2017 Financial and Operating Results" rather than "OPKO Health Reports 2016 Financial and Operating Results" as originally
OPKO Health Reports 2016 Financial and Operating Results
May 09, 2017
U.S. commercial launch of RAYALDEE underway 4Kscore test utilization continues to grow; Level 1 CPT code and CMS pricing in place Pediatric global phase 3 initiated and Japanese registration trial for hGH-CTP commencing shortly Adult study trial data analysis near completion; preparation for
Displaying 21 - 40 of 363